Industry Trend

Site Sections


Menu













© 2023. All Rights reserved.

Overview for ELI LILLY AND COMPANY

All Data per March 3, 2023

Industry:

Drug Manufacturers—General

Last Close:

318.43 USD

Expected Dividend:

1.22 %

Payoffs per Year:

4.0
Business Summary

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.


Competitors View

Ordering

ABBVIE

USA
1.03 4.28%
3.61%
7.39% 5.46% 1.0 4.36
-9.47%
43.02 13.08% 10.52 1.0

CHUGAI PHARMACEUTICAL

JPN
0.96 2.56%
0.0%
22.5% 6.68% 1.0 4.24
-32.13%
32.9 15.38% 77.21 2.0

PFIZER

USA
0.95 3.64%
3.96%
2.76% 3.76% 1.0 3.02
-11.11%
49.05 9.25% 42.54 3.0

ASTRAZENECA

GBR
1.04 4.07%
2.74%
1.15% 3.92% 1.0 11.56
-3.86%
98.3 11.66% 37.27 4.0

DAIICHI SANKYO

JPN
1.05 4.24%
0.0%
0.0% 3.88% 1.0 8.15
-17.26%
35.15 18.52% 61.0 5.0

SANOFI

FRA
1.01 3.78%
4.03%
0.74% 3.58% 1.0 0.57
-12.18%
51.83 7.75% 57.12 6.0

BRISTOL-MYERS SQUIBB

USA
0.98 2.8%
3.1%
1.83% 2.78% 1.0 0.5
-24.44%
34.92 17.8% 32.88 7.0

MERCK & CO.

USA
1.12 3.12%
2.64%
2.24% 3.15% 1.0 2.31
-11.68%
55.47 10.37% 36.13 8.0

KYOWA HAKKO KOGYO

JPN
0.96 1.88%
1.67%
7.74% 2.44% 1.0 3.6
-15.61%
35.6 3.07% 79.96 9.0

GILEAD SCIENCES

USA
1.16 2.74%
3.6%
5.91% 3.26% 1.0 0.15
-42.43%
33.49 -1.11% 31.01 10.0

ELI LILLY AND COMPANY

USA
1.04 2.43%
1.22%
2.86% 2.52% 1.0 7.52
-12.71%
42.91 5.87% 18.4 11.0

ROCHE

CHE
0.92 3.28%
3.51%
0.79% 3.11% 1.0 1.4
-15.85%
37.23 2.14% 26.53 12.0

AMGEN

USA
1.0 2.42%
3.28%
8.46% 3.24% 1.0 3.5
-9.93%
35.72 -5.0% 10.95 13.0

GLAXOSMITHKLINE

GBR
0.96 5.37%
5.27%
0.35% 5.0% -0.5 0.21
-24.56%
49.96 2.63% 19.03 14.0

ASTELLAS PHARMA

JPN
0.96 2.43%
0.0%
1.74% 2.4% 1.0 1.09
-19.06%
27.18 -1.76% 60.96 15.0

OTSUKA HOLDINGS CO., LTD.

JPN
0.93 2.21%
2.54%
0.0% 2.02% 1.0 -0.41
-14.62%
28.52 12.2% 71.29 16.0

BAYER

GER
1.02 2.51%
3.99%
4.7% 2.83% 0.5 -0.36
-58.76%
36.97 -17.89% 27.46 17.0

JOHNSON & JOHNSON

USA
0.98 2.68%
0.0%
0.0% 2.46% 1.0 -1.0
13.03%
44.08 2.58% 40.67 18.0

GRIFOLS SA

ESP
0.98 1.5%
nan%
4.84% 1.7% -0.5 0.24
-46.29%
31.86 -1.95% 31.7 nan


Information for ELI LILLY AND COMPANY

Yield Triangle

Dividend & Close

Close Dividend Return (%)
Year
2012 49.32 1.96 3.97
2013 51.00 1.96 3.84
2014 68.99 1.96 2.84
2015 84.26 2.00 2.37
2016 73.55 2.55 3.47
2017 84.46 2.08 2.46
2018 115.72 2.25 1.94
2019 131.43 2.58 1.96
2020 168.84 2.96 1.75
2021 276.22 3.40 1.23
2023 318.43 3.88 1.22

Fundamentals

Chart